Hims & Hers Health, Inc. (HIMS) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Over the past month, shares of this company have returned +67%, compared to the Zacks S&P 500 composite's +3.5% change. During this period, the Zacks Medical Info Systems industry, which Hims & Hers Health falls in, has lost 1.5%. The key question now is: What could be the stock's futu ...

Hims & Hers Health, Inc. (HIMS) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past month, shares of this company have returned +35%, compared to the Zacks S&P 500 composite's +4.8% change. During this period, the Zacks Medical Info Systems industry, which Hims & Hers Health falls in, has lost 8.2%. The key question now is: What could be the stock's future direction? While m ...

I challenge you to name another $20 stock with more long-term potential. Raging hot inflation has made it harder to find value in anything these days. A $20 bill doesn't go as far as it once did. But don't get discouraged; that money can go a long way if you know where to put it. Yes, even in the stock market, you can still get a lot for $20. Red-hot telehealth company Hims & Hers Health (HIMS 6.63%) recently exploded to nearly $20 per share on a major product announcement. Here's why this is arguably the b ...

GLP-1s could be the product that pushes Hims & Hers over the edge to mainstream adoption. Hims & Hers (HIMS -5.59%) has been a great growth stock since coming public, but it's now starting to turn a profit. In this video, Travis Hoium highlights the company's financials and why the launch of GLP-1 medications could be a game-changer. *Stock prices used were end-of-day prices of May 20, 2024. The video was published on May 21, 2024. ...

Hims & Hers Health Inc. Health platform Hims & Hers Health Inc. announced Monday that it's rolling out injectable weight-loss drugs that cost a fraction of the price of competitors Wegovy and Ozempic. Hims & Hers says its GLP-1 medications contain the same active ingredients as its rivals, but the price starts at $199 per month. For comparison, Wegovy costs around $1,350 per month, and Ozempic is priced at around $935 without insurance. Novo Nordisk produces both drugs. "We've leveraged our size and scale t ...

The company said the shots will be distributed through its pharmacy partners, with plans to expand the program's offerings once "consistent supply" is available. Guidance Doesn't Include Weight-Loss Drug's Impact Key Takeaways Shares of Hims & Hers Health (HIMS) surged close to 28% Monday after the telehealth company said it would begin offering GLP-1 injections as part of its weight-loss package of drugs. The market for weight-loss treatments has exploded in recent years, led by drugs containing the same a ...

Topline Shares of telehealth company Hims & Hers Health closed at a three-year high Monday after the company announced a weight-loss treatment starting at $199 a month that will compete with Novo Nordisk's Wegovy and Ozempic and enter the weight-loss market amid a shortage of branded treatments. Get Forbes Breaking News Text Alerts: We're launching text message alerts so you'll always know the biggest stories shaping the day's headlines. Text "Alerts" to (201) 335-0739 or sign up here. Contra Hims announced ...

Hims & Hers Health Inc (NYSE:HIMS) stock is soaring today, up 29.4% to trade at $18.85 and earlier hitting a three-year high of $20.11. Today's pop comes after the healthcare platform added GLP-1 injections to its weight-loss services, a compounded and cheap version of Novo Nordisk's (NVO) semaglutide (the active ingredient in popular weight-loss drug Wegovy). Since the start of the year, HIMS is sporting a 110% lead, with the 100-day moving average stepping up as support earlier this month. Options bulls a ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell- side) analysts often affect a stock's price, do they really matter? Let's take a look at what these Wall Street heavyweights have to say about Hims & Hers Health, Inc. (HIMS) before we discuss the reliability of brokerage recommendations and how to use them to your advantage. Hims & Hers Health curr ...

With the stock market heating up again, consider investing in disruptive stocks to buy. Betting on disruptive stocks, especially at the right prices, can prove incredibly rewarding. Moreover, with expectations of a sustained bull run ahead, you'd be remiss to ignore the three disruptive stock bets at current prices. Disruptive stocks to buy have the potential to revolutionize their respective industries through their innovative prowess. For investors who can see the potential of disruptive stocks, these bus ...